Preg-MS-PV
Routine data analysis of the drug safety in pregnant multiple sclerosis patients in the context of newly approved, innovative treatments
Preg-MS-PV is a health care research project. The objective of this study is to assess the drug safety in pregnant multiple sclerosis (MS) patients. We describe, to what extent the prescription of contraindicated immunotherapies for pregnant MS patients is avoided in routine health care in accordance with guideline recommendations. Routine data of the BARMER health insurance from 2013 to 2022 is analyzed. With the results of this study we aim to contribute to the drug safety of pregnant MS patients and their unborn children.
None at present
Project details
Responsible persons
Alicia Başoğlu (née Brunßen)
Project period
prospectively April 2024 - March 2025
Sientific advisory board
BARMER health insurance
German-language Multiple Sclerosis and Fertility Register (Deutschsprachiges Multiple Sklerose und Kinderwunschregister, DMSKW)
Central Research Institute of Ambulatory Health Care in the Federal Republic of Germany (Zi)
Institute of Social Medicine and Health Systems Research, Med. Faculty, Otto-Von-Guericke-University Magdeburg
Two patient representatives
Funding
Fifth Academy „Healthcare Research“ for young researchers of the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG)
External links
None at present